Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | GPR6 | P46095 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389266 | 0.94 | GPR119 (0.60) | GPR119CYP2C9GPR6 | |
| SCHEMBL12667483 | 0.94 | GPR119 (0.60) | GPR119CYP2C9GPR6 | |
| SCHEMBL386873 | 0.93 | GPR119 (0.61) | GPR119CYP2C9GPR6 | |
| SCHEMBL390442 | 0.92 | GPR119 (0.63) | GPR119CYP2C9 | |
| SCHEMBL390720 | 0.92 | GPR119 (0.63) | GPR119CYP2C9GPR6 | |
| SCHEMBL1082296 | 0.88 | GPR119 (0.67) | GPR119CYP2C9 | |
| SCHEMBL389537 | 0.86 | GPR119 (0.65) | GPR119CYP2C9 | |
| SCHEMBL388907 | 0.86 | GPR119 (0.65) | GPR119CYP2C9 | |
| SCHEMBL13065559 | 0.85 | GPR119 (0.64) | GPR119CYP2C9 | |
| SCHEMBL385905 | 0.85 | GPR119 (0.64) | GPR119CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546429-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110112060-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112060-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | CYP7A1, CYP27A1, SULT2A1 | GPR119 25/4885CYP2C9 85/4885GPR6 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.